ClinicalTrials.gg
Not yet recruitingNCT07937982RHINOUpdated Nov 16, 2026

Protocol CAUSE-05 RHINO

An observational study in Asthma and Respiratory Health, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Not yet recruiting at 3 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 41 studies in Asthma by National Institute of Allergy and Infectious Diseases (NIAID) — 7 open to participants now, 9 under way, none of them phase 3. Asthma · National Institute of Allergy and Infectious Diseases (NIAID).

Planned enrollment
20th of 23
60 · median 270
Started
2026
with 1 other
Observational
23 of 41
7 open now
Registered
41st of 41
by date

Among the 41 studies in Asthma by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 20th largest by planned enrollment of the 23 observational ones that give a count, is one of 2 that started in 2026, is one of 23 observational ones, and was the 41st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 41 studies in Asthma by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Asthma by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

CAUSE-05/RHINO is an observational study designed to learn how babies' nasal cells grow and change during the first months of life. The study will enroll pregnant mothers in their third trimester and their infants upon delivery for a target population of 60 mother-baby pairs. Researchers will conduct up to 6 study visits and collect serial nasal samples through 4 months of age.

Read the detailed description

This is an observational, multicenter study designed to assess developmental changes in in vivo and in cultured neonatal nasal epithelial cells. The study will enroll pregnant females in their third trimester of pregnancy as well as their infants upon delivery. Approximately 60 mother-infant pairs will be observed from birth to age 4 months to describe early-life developmental patterns of nasal cell gene expression, including genes related to type-II (T2) inflammation, immune response, and epithelial barrier function.

03

Conditions studied

  • Asthma
  • Respiratory Health

Keywords

  • Asthma
  • Allergy
  • Observational Study
  • Infants
  • Birth Cohort
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Pregnant maternal participants from the pre-selected recruitment census tracts designated by the CAUSE program, aged 18 years or older, with a gestational age greater than or equal to 28 weeks, in addition to one offspring of each maternal participant.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to understand and provide
  2. Age 18 years or older
  3. Currently pregnant, with:

    1. Gestational age ≥ 28 weeks as confirmed by participant self-report
    2. Intent to deliver at a participating clinical site labor and delivery (L\&D) center
  4. Agrees to enroll infant into the study at birth
  5. In the case of multiple gestation, agrees to enroll only one infant who will be randomly selected
  6. Have a primary place of residence in one of the pre-selected recruitment census tracts as outlined in the Protocol CAUSE-05 (RHINO) Manual of Procedures (MOP) a. Participants who do not live in the pre-selected census tracts but live within the Office of Management and Budget (OMB) defined Metropolitan Statistical Area and have publicly funded health insurance will qualify for inclusion.

Exclusion criteria

Exclusion Criteria:

  1. Inability or unwillingness to give written or comply with study protocol
  2. Insufficient proficiency in English or Spanish to provide informed consent and complete study procedures
  3. Obstetric complications present and/or anticipated that could, in the opinion of the investigator, impact the study objectives
  4. Pregnancy conceived via donor oocyte (egg donation)
  5. Known plans to move outside the pre-selected recruitment census tracts before the infant reaches 4 months of age
  6. Intent to transfer infant custody (e.g., via adoption or foster placement) within 4 months of birth
  7. Past or current medical problems that are not listed above, which, in the opinion of the investigator, may pose additional risks related to participation in the study, may interfere with the participant's ability to comply with the protocol, or may impact the interpretation of data obtained from the study.

Infants who meet any of the following criteria at the Birth Visit are not eligible for further study participation:

  1. Delivery before 36 weeks gestation
  2. Diagnosed at birth with any medical condition which, in the opinion of the investigator, may pose additional risks related to participation in the study, may interfere with the family's ability to comply with the protocol, or may impact the interpretation of data obtained from the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Pregnant females 18 years and older and their infants upon delivery
06

What researchers measure

Primary outcomes

  1. Gene expression of nasal swab RNA samples

    Gene expression will be measured by whole transcriptome RNA sequencing

    Time frame: 4 months

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Yes — Immunonology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.

Time frame: On average, within 24 months after database lock for the trial.

Access criteria: Open access

Data sharing details ↗ · www.immport.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Sep 2027, 9 months later.

Of 365 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 9 months is below that.

Counting every sponsor, half of 455 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Dec 3, 2026
Primary completionEst.
Sep 28, 2027
CompletionEst.
Sep 28, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937982
Collaborators
Childhood Asthma in Urban Settings (CAUSE), Rho, Inc.
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 3, 2026 (estimated)
Primary completion
Sep 28, 2027 (estimated)
Completion
Sep 28, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

James E Gern, MD
Contact
gern@medicine.wisc.edu
608-263-6201
James E Gern, MD
study chair · University of Wisconsin, Madison
Jo L Wilson, MD
study chair · University of Wisconsin, Madison
Daniel Jackson, MD
study director · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion